source
- Summit pulls $500M share sale a day after announcing itThe developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.BioPharma Dive · 1mo ago↗ source
- Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyA strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.BioPharma Dive · 1mo ago↗ source
- Novartis RNA drug acquired in $12B Avidity deal notches a trial winThe data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.